Rifampin and rifabutin and their metabolism by human liver esterases

Xenobiotica

Volumn 27, Issue 10, 1997, Pages 1015-1024

  Jamis Dow, C A ^a   Katki, A G ^a   Collins, J M ^a   Klecker, R W ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYFLOS; ESTERASE; PARAOXON; RIFABUTIN; RIFAMPICIN;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; LIVER SLICE;

ACETYLATION; ANTIBIOTICS, ANTITUBERCULAR; BIOTRANSFORMATION; ESTERASES; HUMANS; LIVER; MICROSOMES, LIVER; NADP; RIFABUTIN; RIFAMPIN;

EID: 0030764254     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982597239994     Document Type: Article

References (23)

1. ACOCELLA, G., 1978, Clinical Pharmacokinetics of rifampicin. Clinical Pharmacokinetics, 3, 108-127.
2. ACOCELLA, G., BONOLLO, L., MAINARDI, M., MARGAROLI, P. and NICOLIS, F. B., 1974, Kinetic studies on rifampicin. III. Effect of phenobarbital on the half-life of the antibiotic. Tijdschr Gastroenterol, 17, 151-158.
3. ALDRIDGE, W. N., 1953, Serum esterases: Two types of esterases (A and B) hydrolyzing paranitrophenylacetate, propionate, and a method for their determination. Biochemical Journal, 53, 110-119.
4. BACIEWICZ, A. M., SELF, T. H. and BEKEMEYER, W. B., 1987, Update on rifampin drug interactions. Archives of Internal Medicine, 147, 565-568.
5. BROGDEN, R. N. and FITTON, A., 1994, Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs, 47, 983-1009.
6. COCCHIARA, G., STROLIN BENEDETTI, M., VICARIO, G. P., BALLABIO, M., GIOIA, B., VIOGLIO, S. and VIGEVANI, A., 1989, Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica, 19, 769-780.
7. FURESZ, S., 1970, Chemical and biological properties of rifampicin. Antibiotica et Chemotherapia, 16, 316-351.
8. FURESZ, S., SCOTTI, R., PALLANZA, and MAPELLI, E., 1967, Rifampicin: a new rifamycin. 3. Absorption, distribution, and elimination in man. Arzneimittelforschung, 17, 534-537.
9. GRANGE, J. M., WINSTANLEY, P. A. and DAVIES, P. D., 1994, Clinically significant drug interactions with antituberculosis agents. Drug Safety, 11, 242-251.
10. IATSIMIRSKAIA, E., TULEBAEV, S., STOROZHUK, E., UTKIN, I., SMITH, B. A., GERBER, N. and KOUDRIAKOVA, T., 1997, Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clinical Pharmacology and Therapeutics, 61, 554-562.
11. JAMIS-DOW, C. A., KLECKER, R. W., KATKI, A. G. and COLLINS, J. M., 1995, Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemotherapy and Pharmacology, 36, 107-114.
12. LEWIS, R. C., HATFIELD, N. Z. and NARANG, P. K., 1991, A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biological fluids by high-performance liquid chromatography (HPLC). Pharmaceutical Research, 8, 1434-1440.
13. MAE, T., HOSOE, K., FUJII, K., YAMASHITA, K., YAMANE, T., HIDAKA, T.and OASHI, T., 1996, In vitro metabolism of a rifamycin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoform. Xenobiotica, 26, 793-802.
14. MAGGI, N., FURESZ, S., PALLANZA, R. and PELIZZA, G., 1969, Rifampicin desacetylation in the human organism. Arzneimittelforschung, 19, 651-654.
15. MAGGI, N., VIGEVANI, A. and PALLANZA, R., 1968, Desacetyl-rifamycins: preparation and antibacterial properties. Experientia, 24, 209-211.
16. MANDELL, G. L. and PETRI, JR., W. A., 1996, Drugs used in the chemotherapy of tuberculosis, Mvcobacterium avium complex disease and leprosy. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn, edited by Joel G. Hardman, Lee E. Limbird, Perry B. Molinoff, Raymond W. Ruddon and Alfred Goodman Gilman (New York: McGraw-Hill), pp. 1155-1174.
17. The Merck Index, 12 edn, 1996, edited by S. Budavari (Rahway : Merck & Co.), pp. 1413-1414.
18. PARKINSON, A., 1996, Biotransformation of xenobiotics. In Casaret & Doull's Toxicology: The Basic Science of Poisons, 5th edn, edited by C. D. Klaassen (New York: McGraw-Hill), pp. 113-186.
19. SKINNER, M. H., HSIEH, M., TORSETH, J., PAULOIN, D., BHATIA, G., HARKONEN, S., MERIGAN, T. C. and BLASCHKE, T. F., 1989, Pharmacokinetics of rifabutin. Antimicrobial Agents and Chemotherapy, 33, 1237-1241.
20. STROLIN BENEDETTI, M. and DOSTERT, P., 1994, Induction and autoinduction properties of rifamycin derivatives : a review of animal and human studies. Environmental Health Perspectives, 102 (suppl. 9), 101-105.
21. TRAPNELL, C. B., JAMIS-DOW, C., KLECKER, R. W. and COLLINS, J. M., 1997, Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P450 3A4: relevance to clinical interaction with fluconazole. Antimicrobial Agents and Chemotherapy, 41, 924-926.
22. VITAL DURAND, D., HAMPDEN, C., BOOBIS, A. R., PARK, B. K. and DAVIES, D. S., 1986, Induction of mixed function oxidase in man by rifapentine (MDL 473), a long-acting rifamycin derivative. British Journal of Clinical Pharmacology, 21, 1-7.
23. WEBER, A., OPHEIM, K. E., SMITH, A. L. and WONG, K., 1983, High-pressure liquid chromatographic quantitation of rifampin and its two major metabolites in urine and serum. Review of Infectious Diseases, 5 (suppl. 3), S433-439.